GeneDx Faces Class Action Over Alleged Securities Fraud

The legal action alleges that GeneDx violated the Securities Exchange Act of 1934 by issuing false and misleading statements to shareholders. These claims emerged following the company's Q1 2026 financial report released on May 4, 2026. During that disclosure, GeneDx revealed a significant decline in adjusted gross margins, lowered its earnings projections, and recorded a $31.3 million impairment charge tied to Fabric Genomics.

Shareholders who incurred losses as a result of these developments have until August 3, 2026, to contact Brian Schall of The Schall Law Firm to discuss potential participation. While the class has yet to be certified, the firm is currently gathering claimants to recover damages stemming from the alleged market deception. Investors may reach the firm at its Los Angeles office or via its website, though they remain absent class members until formal certification occurs.